The U.S. Food and Drug Administration (FDA) has added a boxed warning to the label for Lecanemab (LEQEMBI), effective 2026-06-30. This significant update highlights the risk of amyloid related imaging abnormalities (ARIA), specifically noting ARIA with edema (ARIA-E), associated with the drug. Monoclonal antibodies targeting aggregated forms of beta amyloid, including LEQEMBI, can cause these abnormalities.
Background
Lecanemab, marketed as LEQEMBI, is a monoclonal antibody directed against aggregated forms of beta amyloid. The inclusion of a boxed warning, also known as a black box warning, represents the strongest warning the FDA can require for prescription medications. This type of warning is issued when there is reasonable evidence of a serious hazard associated with the drug. The specific warning for LEQEMBI addresses amyloid related imaging abnormalities (ARIA), which can manifest as ARIA with edema (ARIA-E).
What this means
The addition of a boxed warning to the Lecanemab (LEQEMBI) label signals a critical safety consideration for healthcare providers and patients. Clinicians prescribing LEQEMBI must be aware of the potential for amyloid related imaging abnormalities (ARIA), including ARIA with edema (ARIA-E), and monitor patients accordingly. This warning underscores the importance of understanding and managing these potential adverse events. Researchers and patient advocates should note the FDA's emphasis on this specific safety concern for drugs in this class.
Source
This label revision was issued by the U.S. Food and Drug Administration (FDA), effective 2026-06-30. The details of the boxed warning for Lecanemab (LEQEMBI) are available on dailymed.nlm.nih.gov, an official service of the National Library of Medicine.